Abstracts tagged "Anti-TNF therapy and rituximab"

Abstract Number: 1535 • 2014 ACR/ARHP Annual Meeting
Use of Rituximab Compared to Anti-Tnf Agents As Second and Third Line Therapy in Patients with Rheumatoid Arthritis: A Report from the rhumadata® Clinical Database and registry
Denis Choquette¹, Jean-Pierre Raynauld¹, Jean Pierre Pelletier¹, Boulos Haraoui¹, Louis Bessette², Edith Villeneuve¹, Marie-Anaïs Rémillard³, Isabelle Fortin⁴, Diane Sauvageau¹ and Louis Coupal¹, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Rheumatology, Centre d’ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada, ³Rhumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁴Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada
Background/Purpose: The order of use of biologic agents after failing a TNF inhibitor is still a question for debate. Phase III trial data in TNF-IR…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Abstracts tagged "Anti-TNF therapy and rituximab"

Use of Rituximab Compared to Anti-Tnf Agents As Second and Third Line Therapy in Patients with Rheumatoid Arthritis: A Report from the rhumadata® Clinical Database and registry